Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Samrat Pharmachem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was -784.10%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Samrat Pharmachem's 3-Year ROIIC % or its related term are showing as below:
BOM:530125's 3-Year ROIIC % is ranked worse than 98.95% of 1531
companies
in the Chemicals industry
Industry Median: 0.03
vs BOM:530125: -784.10
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Samrat Pharmachem 3-Year ROIIC % Related Terms
Samrat Pharmachem 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Samrat Pharmachem's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem 3-Year ROIIC % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's 3-Year ROIIC % falls into.
Samrat Pharmachem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -28.594 (Mar. 2026) - 172.6128041 (Mar. 2023) )
/
( 753.692 (Mar. 2026) - 728.031 (Mar. 2023) )
=
-201.2068041
/
25.661
=
-784.10%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Samrat Pharmachem (BOM:530125) has a 3-Year ROIIC % of -784.10 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Samrat Pharmachem and its competitors. According to the industry distribution chart, Samrat Pharmachem ranks #1515 out of 1531 companies in the Chemicals industry, placing it in the top 99%.
Is Samrat Pharmachem's 3-Year ROIIC % too high?
Samrat Pharmachem's current 3-Year ROIIC % is -784.10. Based on the distribution chart, Samrat Pharmachem ranks #1515 out of 1531 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's 3-Year ROIIC % compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #1515 out of 1531 companies for 3-Year ROIIC %. This places Samrat Pharmachem in the lower half of its industry. The industry median 3-Year ROIIC % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Chemicals company?
The median 3-Year ROIIC % among Chemicals companies is 0.03, based on 1,531 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median 3-Year ROIIC % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current 3-Year ROIIC % is -784.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.16, compared to a current price of ₹236.95 — trading 34.6% below its estimated fair value. The current 3-Year ROIIC % is -784.10. Samrat Pharmachem's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current 3-Year ROIIC % is -784.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹236.95 is trading 34.6% below its estimated GF Value™ of ₹362.16.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
3-Year ROIIC %: -784.10
GF Value™: ₹362.16 vs. price of ₹236.95 (34.6% below fair value)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score
Get the complete analysis for BOM:530125
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
